⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
GMAB News
Genmab A/S ADS
Genmab Announces Topline Results for Epcoritamab (DuoBody ® CD3xCD20) from Phase 3 EPCORE ® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
businesswire.com
GMAB
Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
globenewswire.com
GMAB
Genmab Partners with Anthropic to Accelerate Research and Development Through Agentic Artificial Intelligence
globenewswire.com
GMAB
Genmab to Present at the 44th Annual J.P. Morgan Healthcare Conference
globenewswire.com
GMAB
Genmab Portfolio Prioritization Update
businesswire.com
GMAB
Genmab Portfolio Prioritization Update
globenewswire.com
GMAB
Immunotherapies Replacing Chemotherapy as Blood Cancer Market to Hit $13B by 2030
prnewswire.com
GTBP
REGN
GMAB
AUTL
LYEL
Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period
businesswire.com
GMAB
MRUS
Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period
globenewswire.com
GMAB
MRUS
Genmab to Hold 2025 R&D Update and ASH Data Review Meeting
globenewswire.com
GMAB